WILMINGTON, Mass., Aug. 28, 2014 /PRNewswire/ -- Marking a major
milestone for the Company, Implant Sciences Corporation
(OTCQB: IMSC), a high technology supplier of systems and sensors
for homeland security and defense markets, announced today that its
QS-B220 desktop explosives trace detector has successfully
completed the certification process for the United States Transportation Security
Administration's (TSA) Explosive Trace Detection (ETD)
qualification requirements for aviation checkpoint and checked
baggage screening. The QS-B220 becomes the first ETD with a
non-radioactive source to be added to the TSA's Qualified Product
List (QPL).
"The addition of the QS-B220 to TSA's QPL is the single most
significant achievement in our Company's history," stated Implant
Sciences' President and CEO, Glenn D.
Bolduc. "We're very proud to be able to deliver this
innovative product for the protection of travelers in our country.
Every member of the Implant Sciences team has done a phenomenal job
of getting us to this point. We would also like to recognize the
support we have received from our shareholders and other investors
over the last few years while we have been pursuing this most
significant qualification. Without their support this would not
have been achievable."
"Being added to TSA's QPL is one of the highest levels of
recognition in the security industry and one of the most difficult
to achieve. The team at Implant Sciences has been nothing short of
remarkable and focused in preparing the QS-B220 for this
challenge," continued Todd
Silvestri, VP of Technology for Implant Sciences
Corporation. "Implant Sciences has highlighted their deep domain
knowledge in the development and commercialization of this unit,
and we are excited as a company to have cleared the last major
hurdle in the U.S. aviation market."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCalâ„¢ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., STAC in France, the German
Ministry of the Interior, and the Ministry of Public Safety in
China. It also received a GSN 2013
Homeland Security Award for "Best Explosives Detection
Solution". All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
our explosives detection products and technologies (including any
new products we may develop) may not be accepted by the
Transportation Security Administration or by other U.S. or foreign
government and law enforcement agencies or commercial consumers of
security products; economic, political and other risks associated
with international sales and operations could adversely affect our
sales; our business is subject to intense competition and rapid
technological change, and our success will depend on our ability to
develop and introduce new products; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including our most recent Forms 10-K, 10-Q and
8-K. Such statements are based on management's current expectations
and assumptions which could differ materially from the
forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation